nodes	percent_of_prediction	percent_of_DWPC	metapath
Ergotamine—ABCB1—Ezetimibe—atherosclerosis	0.0772	0.152	CbGbCtD
Ergotamine—ABCB1—Simvastatin—atherosclerosis	0.0718	0.141	CbGbCtD
Ergotamine—ABCB1—Pravastatin—atherosclerosis	0.0703	0.138	CbGbCtD
Ergotamine—ABCB1—Lovastatin—atherosclerosis	0.0703	0.138	CbGbCtD
Ergotamine—CYP3A4—Ezetimibe—atherosclerosis	0.0463	0.0909	CbGbCtD
Ergotamine—CYP3A4—Rosuvastatin—atherosclerosis	0.0463	0.0909	CbGbCtD
Ergotamine—CYP3A4—Simvastatin—atherosclerosis	0.043	0.0845	CbGbCtD
Ergotamine—CYP3A4—Lovastatin—atherosclerosis	0.0421	0.0827	CbGbCtD
Ergotamine—CYP3A4—Pravastatin—atherosclerosis	0.0421	0.0827	CbGbCtD
Ergotamine—HTR2A—arteriole—atherosclerosis	0.00818	0.146	CbGeAlD
Ergotamine—Numbness—Pravastatin—atherosclerosis	0.00496	0.0562	CcSEcCtD
Ergotamine—HTR2A—vein—atherosclerosis	0.00488	0.087	CbGeAlD
Ergotamine—Sensory loss—Pravastatin—atherosclerosis	0.00475	0.0537	CcSEcCtD
Ergotamine—HTR1B—artery—atherosclerosis	0.00413	0.0737	CbGeAlD
Ergotamine—HTR1D—artery—atherosclerosis	0.004	0.0713	CbGeAlD
Ergotamine—HTR2A—hindlimb—atherosclerosis	0.00324	0.0578	CbGeAlD
Ergotamine—HTR1B—blood vessel—atherosclerosis	0.00322	0.0574	CbGeAlD
Ergotamine—HTR1D—blood vessel—atherosclerosis	0.00311	0.0556	CbGeAlD
Ergotamine—HTR2A—appendage—atherosclerosis	0.00278	0.0496	CbGeAlD
Ergotamine—Myalgia—Rosuvastatin—atherosclerosis	0.00214	0.0242	CcSEcCtD
Ergotamine—Hypoaesthesia—Niacin—atherosclerosis	0.00209	0.0236	CcSEcCtD
Ergotamine—Hypoaesthesia—Pravastatin—atherosclerosis	0.00206	0.0233	CcSEcCtD
Ergotamine—HTR2A—artery—atherosclerosis	0.00199	0.0354	CbGeAlD
Ergotamine—Vertigo—Lovastatin—atherosclerosis	0.00191	0.0216	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00187	0.0211	CcSEcCtD
Ergotamine—Paraesthesia—Rosuvastatin—atherosclerosis	0.00184	0.0208	CcSEcCtD
Ergotamine—Myalgia—Lovastatin—atherosclerosis	0.00181	0.0205	CcSEcCtD
Ergotamine—Hypertension—Ezetimibe—atherosclerosis	0.0018	0.0204	CcSEcCtD
Ergotamine—Vertigo—Simvastatin—atherosclerosis	0.00179	0.0202	CcSEcCtD
Ergotamine—Myalgia—Ezetimibe—atherosclerosis	0.00178	0.0201	CcSEcCtD
Ergotamine—Pain—Rosuvastatin—atherosclerosis	0.00175	0.0198	CcSEcCtD
Ergotamine—Myalgia—Simvastatin—atherosclerosis	0.00169	0.0192	CcSEcCtD
Ergotamine—HTR2A—endothelium—atherosclerosis	0.00168	0.0299	CbGeAlD
Ergotamine—Vertigo—Niacin—atherosclerosis	0.00164	0.0186	CcSEcCtD
Ergotamine—Vertigo—Pravastatin—atherosclerosis	0.00162	0.0183	CcSEcCtD
Ergotamine—HTR1D—connective tissue—atherosclerosis	0.0016	0.0285	CbGeAlD
Ergotamine—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00158	0.0179	CcSEcCtD
Ergotamine—Paraesthesia—Lovastatin—atherosclerosis	0.00156	0.0176	CcSEcCtD
Ergotamine—Myalgia—Niacin—atherosclerosis	0.00156	0.0176	CcSEcCtD
Ergotamine—Hypertension—Pravastatin—atherosclerosis	0.00155	0.0176	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00155	0.0176	CcSEcCtD
Ergotamine—HTR2A—blood vessel—atherosclerosis	0.00155	0.0276	CbGeAlD
Ergotamine—Myalgia—Pravastatin—atherosclerosis	0.00153	0.0173	CcSEcCtD
Ergotamine—Paraesthesia—Ezetimibe—atherosclerosis	0.00153	0.0173	CcSEcCtD
Ergotamine—Pain—Lovastatin—atherosclerosis	0.00148	0.0168	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.00148	0.0167	CcSEcCtD
Ergotamine—Asthenia—Rosuvastatin—atherosclerosis	0.00147	0.0166	CcSEcCtD
Ergotamine—Paraesthesia—Simvastatin—atherosclerosis	0.00146	0.0165	CcSEcCtD
Ergotamine—Pain—Ezetimibe—atherosclerosis	0.00146	0.0165	CcSEcCtD
Ergotamine—Tachycardia—Niacin—atherosclerosis	0.00146	0.0165	CcSEcCtD
Ergotamine—Pruritus—Rosuvastatin—atherosclerosis	0.00145	0.0164	CcSEcCtD
Ergotamine—HTR1B—cardiovascular system—atherosclerosis	0.00143	0.0256	CbGeAlD
Ergotamine—HTR1D—cardiovascular system—atherosclerosis	0.00139	0.0248	CbGeAlD
Ergotamine—Pain—Simvastatin—atherosclerosis	0.00139	0.0157	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Niacin—atherosclerosis	0.00136	0.0154	CcSEcCtD
Ergotamine—Paraesthesia—Niacin—atherosclerosis	0.00134	0.0151	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.00134	0.0151	CcSEcCtD
Ergotamine—Paraesthesia—Pravastatin—atherosclerosis	0.00132	0.0149	CcSEcCtD
Ergotamine—HTR2B—cardiovascular system—atherosclerosis	0.00129	0.0231	CbGeAlD
Ergotamine—Pain—Niacin—atherosclerosis	0.00128	0.0144	CcSEcCtD
Ergotamine—Pain—Pravastatin—atherosclerosis	0.00126	0.0142	CcSEcCtD
Ergotamine—Asthenia—Lovastatin—atherosclerosis	0.00125	0.0141	CcSEcCtD
Ergotamine—Pruritus—Lovastatin—atherosclerosis	0.00123	0.0139	CcSEcCtD
Ergotamine—Asthenia—Ezetimibe—atherosclerosis	0.00122	0.0138	CcSEcCtD
Ergotamine—Nausea—Rosuvastatin—atherosclerosis	0.00122	0.0138	CcSEcCtD
Ergotamine—Pruritus—Ezetimibe—atherosclerosis	0.0012	0.0136	CcSEcCtD
Ergotamine—Asthenia—Simvastatin—atherosclerosis	0.00117	0.0132	CcSEcCtD
Ergotamine—HTR1A—cardiovascular system—atherosclerosis	0.00116	0.0207	CbGeAlD
Ergotamine—Pruritus—Simvastatin—atherosclerosis	0.00115	0.013	CcSEcCtD
Ergotamine—HTR2B—adipose tissue—atherosclerosis	0.00114	0.0203	CbGeAlD
Ergotamine—Vomiting—Lovastatin—atherosclerosis	0.0011	0.0125	CcSEcCtD
Ergotamine—Vomiting—Ezetimibe—atherosclerosis	0.00108	0.0122	CcSEcCtD
Ergotamine—Asthenia—Niacin—atherosclerosis	0.00107	0.0121	CcSEcCtD
Ergotamine—ADRA1A—cardiovascular system—atherosclerosis	0.00107	0.019	CbGeAlD
Ergotamine—Pruritus—Niacin—atherosclerosis	0.00106	0.0119	CcSEcCtD
Ergotamine—Asthenia—Pravastatin—atherosclerosis	0.00105	0.0119	CcSEcCtD
Ergotamine—Pruritus—Pravastatin—atherosclerosis	0.00104	0.0118	CcSEcCtD
Ergotamine—Vomiting—Simvastatin—atherosclerosis	0.00103	0.0117	CcSEcCtD
Ergotamine—Nausea—Lovastatin—atherosclerosis	0.00103	0.0117	CcSEcCtD
Ergotamine—ABCB1—blood vessel—atherosclerosis	0.00101	0.0181	CbGeAlD
Ergotamine—Nausea—Ezetimibe—atherosclerosis	0.00101	0.0114	CcSEcCtD
Ergotamine—Nausea—Simvastatin—atherosclerosis	0.000965	0.0109	CcSEcCtD
Ergotamine—Vomiting—Niacin—atherosclerosis	0.000948	0.0107	CcSEcCtD
Ergotamine—ADRA1A—adipose tissue—atherosclerosis	0.000941	0.0168	CbGeAlD
Ergotamine—Vomiting—Pravastatin—atherosclerosis	0.000934	0.0106	CcSEcCtD
Ergotamine—ADRA2A—connective tissue—atherosclerosis	0.000933	0.0166	CbGeAlD
Ergotamine—Nausea—Niacin—atherosclerosis	0.000886	0.01	CcSEcCtD
Ergotamine—Nausea—Pravastatin—atherosclerosis	0.000872	0.00987	CcSEcCtD
Ergotamine—HTR2A—connective tissue—atherosclerosis	0.000793	0.0141	CbGeAlD
Ergotamine—ADRA2A—adipose tissue—atherosclerosis	0.000716	0.0128	CbGeAlD
Ergotamine—HTR2A—cardiovascular system—atherosclerosis	0.00069	0.0123	CbGeAlD
Ergotamine—ADRA1A—liver—atherosclerosis	0.00066	0.0118	CbGeAlD
Ergotamine—CYP1A2—liver—atherosclerosis	0.000546	0.00974	CbGeAlD
Ergotamine—ABCB1—cardiovascular system—atherosclerosis	0.000452	0.00807	CbGeAlD
Ergotamine—HTR2A—liver—atherosclerosis	0.000427	0.00761	CbGeAlD
Ergotamine—ABCB1—adipose tissue—atherosclerosis	0.000399	0.00711	CbGeAlD
Ergotamine—CYP3A4—liver—atherosclerosis	0.000395	0.00705	CbGeAlD
Ergotamine—ABCB1—liver—atherosclerosis	0.00028	0.00499	CbGeAlD
Ergotamine—CYP3A4—Metabolism—LIPC—atherosclerosis	1.51e-05	4.35e-05	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—IL6—atherosclerosis	1.51e-05	4.35e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling by GPCR—AKT1—atherosclerosis	1.5e-05	4.34e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—NFKB1—atherosclerosis	1.5e-05	4.34e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—SERPINE1—atherosclerosis	1.5e-05	4.34e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—PIK3CG—atherosclerosis	1.5e-05	4.33e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling by GPCR—IL6—atherosclerosis	1.5e-05	4.33e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CAV1—atherosclerosis	1.5e-05	4.33e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—APOC3—atherosclerosis	1.5e-05	4.32e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—APOA1—atherosclerosis	1.49e-05	4.32e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—NOS3—atherosclerosis	1.49e-05	4.31e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—LPL—atherosclerosis	1.49e-05	4.31e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—LDLR—atherosclerosis	1.49e-05	4.3e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—MAPK8—atherosclerosis	1.48e-05	4.26e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling by GPCR—AKT1—atherosclerosis	1.47e-05	4.25e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—PIK3CG—atherosclerosis	1.47e-05	4.24e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—CXCL8—atherosclerosis	1.47e-05	4.24e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—MAPK3—atherosclerosis	1.46e-05	4.22e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—GPX1—atherosclerosis	1.45e-05	4.2e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CETP—atherosclerosis	1.45e-05	4.2e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—ESR1—atherosclerosis	1.44e-05	4.17e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—INS—atherosclerosis	1.44e-05	4.17e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—NOS3—atherosclerosis	1.44e-05	4.16e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—SERPINE1—atherosclerosis	1.44e-05	4.15e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—MAPK3—atherosclerosis	1.44e-05	4.15e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—NOS3—atherosclerosis	1.43e-05	4.14e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—F2—atherosclerosis	1.43e-05	4.12e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—MMP9—atherosclerosis	1.43e-05	4.12e-05	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—IL6—atherosclerosis	1.42e-05	4.1e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—INS—atherosclerosis	1.42e-05	4.1e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CCL2—atherosclerosis	1.42e-05	4.1e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—CD36—atherosclerosis	1.42e-05	4.09e-05	CbGpPWpGaD
Ergotamine—ADRA1D—GPCR downstream signaling—AKT1—atherosclerosis	1.42e-05	4.09e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—ALB—atherosclerosis	1.42e-05	4.09e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—NFKB1—atherosclerosis	1.41e-05	4.07e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—MAPK3—atherosclerosis	1.41e-05	4.06e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CCL2—atherosclerosis	1.4e-05	4.03e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—IGF1—atherosclerosis	1.4e-05	4.03e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—IL6—atherosclerosis	1.39e-05	4.03e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—VEGFA—atherosclerosis	1.39e-05	4.02e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—SCARB1—atherosclerosis	1.39e-05	4.02e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—INS—atherosclerosis	1.39e-05	4.02e-05	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—AKT1—atherosclerosis	1.39e-05	4.01e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—MAPK8—atherosclerosis	1.39e-05	4.01e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling by GPCR—AKT1—atherosclerosis	1.38e-05	3.99e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—STAT3—atherosclerosis	1.38e-05	3.98e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—IGF1—atherosclerosis	1.37e-05	3.97e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—NOS3—atherosclerosis	1.37e-05	3.96e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CCL2—atherosclerosis	1.37e-05	3.95e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—PIK3CG—atherosclerosis	1.36e-05	3.94e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—VEGFA—atherosclerosis	1.36e-05	3.94e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—NOS3—atherosclerosis	1.35e-05	3.91e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—STAT3—atherosclerosis	1.35e-05	3.9e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—IGF1—atherosclerosis	1.34e-05	3.88e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—MTHFR—atherosclerosis	1.34e-05	3.88e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—MMP9—atherosclerosis	1.33e-05	3.83e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—SERPINE1—atherosclerosis	1.33e-05	3.83e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—CXCL8—atherosclerosis	1.32e-05	3.82e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PPARA—atherosclerosis	1.32e-05	3.81e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—MAPK3—atherosclerosis	1.32e-05	3.8e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—HMGCR—atherosclerosis	1.31e-05	3.8e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—NFKB1—atherosclerosis	1.31e-05	3.79e-05	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—AKT1—atherosclerosis	1.31e-05	3.78e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—MAPK3—atherosclerosis	1.31e-05	3.77e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—SERPINE1—atherosclerosis	1.3e-05	3.77e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—HMOX1—atherosclerosis	1.3e-05	3.76e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—INS—atherosclerosis	1.29e-05	3.73e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—MAPK8—atherosclerosis	1.29e-05	3.73e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—MAPK3—atherosclerosis	1.29e-05	3.72e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—AKT1—atherosclerosis	1.29e-05	3.72e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—VEGFA—atherosclerosis	1.28e-05	3.7e-05	CbGpPWpGaD
Ergotamine—ADRA2B—GPCR downstream signaling—AKT1—atherosclerosis	1.28e-05	3.69e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—CXCL8—atherosclerosis	1.28e-05	3.69e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—TGFB1—atherosclerosis	1.28e-05	3.69e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—SERPINE1—atherosclerosis	1.28e-05	3.69e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—AGT—atherosclerosis	1.28e-05	3.69e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—CXCL8—atherosclerosis	1.27e-05	3.67e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CCL2—atherosclerosis	1.27e-05	3.67e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—STAT3—atherosclerosis	1.27e-05	3.66e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—NOS3—atherosclerosis	1.27e-05	3.65e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—IL6—atherosclerosis	1.26e-05	3.64e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—TGFB1—atherosclerosis	1.25e-05	3.61e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—APOE—atherosclerosis	1.25e-05	3.61e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—IGF1—atherosclerosis	1.25e-05	3.61e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—APOB—atherosclerosis	1.25e-05	3.6e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—NOS3—atherosclerosis	1.24e-05	3.6e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—PTGS2—atherosclerosis	1.24e-05	3.58e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—CAV1—atherosclerosis	1.24e-05	3.58e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—APOA1—atherosclerosis	1.24e-05	3.57e-05	CbGpPWpGaD
Ergotamine—HTR1A—GPCR downstream signaling—AKT1—atherosclerosis	1.23e-05	3.57e-05	CbGpPWpGaD
Ergotamine—HTR2C—GPCR downstream signaling—AKT1—atherosclerosis	1.23e-05	3.55e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—NOS3—atherosclerosis	1.22e-05	3.52e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CXCL8—atherosclerosis	1.22e-05	3.52e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—IL6—atherosclerosis	1.22e-05	3.51e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—GSTM1—atherosclerosis	1.21e-05	3.5e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—MAPK3—atherosclerosis	1.21e-05	3.5e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—IL6—atherosclerosis	1.21e-05	3.49e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—MMP9—atherosclerosis	1.2e-05	3.46e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—VEGFA—atherosclerosis	1.19e-05	3.44e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—LPL—atherosclerosis	1.19e-05	3.44e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—SERPINE1—atherosclerosis	1.19e-05	3.43e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—NFKB1—atherosclerosis	1.18e-05	3.42e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—STAT3—atherosclerosis	1.18e-05	3.41e-05	CbGpPWpGaD
Ergotamine—ADRA1B—GPCR downstream signaling—AKT1—atherosclerosis	1.18e-05	3.4e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—TGFB1—atherosclerosis	1.17e-05	3.39e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ABCA1—atherosclerosis	1.17e-05	3.38e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—MAPK8—atherosclerosis	1.16e-05	3.36e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—GPX1—atherosclerosis	1.16e-05	3.36e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—AKT1—atherosclerosis	1.16e-05	3.36e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—IL6—atherosclerosis	1.16e-05	3.34e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—MMP9—atherosclerosis	1.16e-05	3.34e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—MMP9—atherosclerosis	1.15e-05	3.32e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—NFKB1—atherosclerosis	1.14e-05	3.3e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—NFKB1—atherosclerosis	1.14e-05	3.29e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—NOS3—atherosclerosis	1.13e-05	3.27e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—CD36—atherosclerosis	1.13e-05	3.27e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PIK3CG—atherosclerosis	1.13e-05	3.26e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—MAPK3—atherosclerosis	1.13e-05	3.25e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—MAPK8—atherosclerosis	1.12e-05	3.25e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CXCL8—atherosclerosis	1.12e-05	3.24e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—AKT1—atherosclerosis	1.12e-05	3.24e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—MAPK8—atherosclerosis	1.12e-05	3.23e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—AKT1—atherosclerosis	1.12e-05	3.22e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CXCL8—atherosclerosis	1.1e-05	3.19e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MMP9—atherosclerosis	1.1e-05	3.18e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—TGFB1—atherosclerosis	1.09e-05	3.16e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—NFKB1—atherosclerosis	1.09e-05	3.15e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PPARG—atherosclerosis	1.09e-05	3.15e-05	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—AKT1—atherosclerosis	1.08e-05	3.13e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CXCL8—atherosclerosis	1.08e-05	3.12e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—VEGFA—atherosclerosis	1.08e-05	3.11e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—MTHFR—atherosclerosis	1.07e-05	3.1e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MAPK8—atherosclerosis	1.07e-05	3.09e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—INS—atherosclerosis	1.07e-05	3.09e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—AKT1—atherosclerosis	1.07e-05	3.08e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—IL6—atherosclerosis	1.07e-05	3.08e-05	CbGpPWpGaD
Ergotamine—HTR2A—GPCR downstream signaling—AKT1—atherosclerosis	1.07e-05	3.08e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—STAT3—atherosclerosis	1.06e-05	3.08e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PPARA—atherosclerosis	1.05e-05	3.04e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—IL6—atherosclerosis	1.05e-05	3.03e-05	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—AKT1—atherosclerosis	1.04e-05	3.02e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—VEGFA—atherosclerosis	1.04e-05	3e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—VEGFA—atherosclerosis	1.03e-05	2.98e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—IL6—atherosclerosis	1.03e-05	2.97e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—STAT3—atherosclerosis	1.03e-05	2.97e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—STAT3—atherosclerosis	1.02e-05	2.95e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—AGT—atherosclerosis	1.02e-05	2.94e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—MAPK3—atherosclerosis	1.02e-05	2.94e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MMP9—atherosclerosis	1.01e-05	2.93e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—HMOX1—atherosclerosis	1e-05	2.9e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CXCL8—atherosclerosis	1e-05	2.9e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—NFKB1—atherosclerosis	1e-05	2.9e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MMP9—atherosclerosis	9.99e-06	2.89e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—APOE—atherosclerosis	9.98e-06	2.88e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—CAV1—atherosclerosis	9.89e-06	2.86e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—VEGFA—atherosclerosis	9.89e-06	2.86e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—NFKB1—atherosclerosis	9.88e-06	2.85e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MAPK8—atherosclerosis	9.87e-06	2.85e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—TGFB1—atherosclerosis	9.87e-06	2.85e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—APOA1—atherosclerosis	9.86e-06	2.85e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—AKT1—atherosclerosis	9.84e-06	2.84e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—MAPK3—atherosclerosis	9.82e-06	2.84e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—ALB—atherosclerosis	9.79e-06	2.83e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—STAT3—atherosclerosis	9.79e-06	2.83e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MMP9—atherosclerosis	9.78e-06	2.82e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—MAPK3—atherosclerosis	9.77e-06	2.82e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MAPK8—atherosclerosis	9.71e-06	2.81e-05	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—AKT1—atherosclerosis	9.7e-06	2.8e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—AKT1—atherosclerosis	9.69e-06	2.8e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—NFKB1—atherosclerosis	9.67e-06	2.79e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—IL6—atherosclerosis	9.62e-06	2.78e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—APOB—atherosclerosis	9.62e-06	2.78e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—IL6—atherosclerosis	9.55e-06	2.76e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—TGFB1—atherosclerosis	9.53e-06	2.75e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MAPK8—atherosclerosis	9.51e-06	2.75e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—AKT1—atherosclerosis	9.48e-06	2.74e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—TGFB1—atherosclerosis	9.48e-06	2.74e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—IL6—atherosclerosis	9.42e-06	2.72e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—NOS3—atherosclerosis	9.36e-06	2.71e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GSTM1—atherosclerosis	9.36e-06	2.7e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MAPK3—atherosclerosis	9.35e-06	2.7e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—LPL—atherosclerosis	9.19e-06	2.65e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—VEGFA—atherosclerosis	9.11e-06	2.63e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MMP9—atherosclerosis	9.09e-06	2.62e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—TGFB1—atherosclerosis	9.07e-06	2.62e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—STAT3—atherosclerosis	9.02e-06	2.61e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PIK3CG—atherosclerosis	9.01e-06	2.6e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—NFKB1—atherosclerosis	8.99e-06	2.6e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—VEGFA—atherosclerosis	8.97e-06	2.59e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GPX1—atherosclerosis	8.96e-06	2.59e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—STAT3—atherosclerosis	8.88e-06	2.57e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—AKT1—atherosclerosis	8.88e-06	2.57e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—IL6—atherosclerosis	8.85e-06	2.56e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MAPK8—atherosclerosis	8.84e-06	2.55e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—AKT1—atherosclerosis	8.81e-06	2.55e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—VEGFA—atherosclerosis	8.78e-06	2.54e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CD36—atherosclerosis	8.73e-06	2.52e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—AKT1—atherosclerosis	8.69e-06	2.51e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—STAT3—atherosclerosis	8.69e-06	2.51e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PPARG—atherosclerosis	8.69e-06	2.51e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MAPK3—atherosclerosis	8.62e-06	2.49e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PTGS2—atherosclerosis	8.57e-06	2.47e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—INS—atherosclerosis	8.53e-06	2.46e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MAPK3—atherosclerosis	8.48e-06	2.45e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—TGFB1—atherosclerosis	8.36e-06	2.42e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MAPK3—atherosclerosis	8.31e-06	2.4e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—MTHFR—atherosclerosis	8.27e-06	2.39e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—IL6—atherosclerosis	8.24e-06	2.38e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—TGFB1—atherosclerosis	8.23e-06	2.38e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—AKT1—atherosclerosis	8.17e-06	2.36e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—VEGFA—atherosclerosis	8.16e-06	2.36e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PPARA—atherosclerosis	8.12e-06	2.34e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—STAT3—atherosclerosis	8.08e-06	2.33e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—TGFB1—atherosclerosis	8.06e-06	2.33e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—AGT—atherosclerosis	7.86e-06	2.27e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—ALB—atherosclerosis	7.82e-06	2.26e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MAPK3—atherosclerosis	7.72e-06	2.23e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—APOE—atherosclerosis	7.7e-06	2.22e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CAV1—atherosclerosis	7.63e-06	2.2e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—APOA1—atherosclerosis	7.61e-06	2.2e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—AKT1—atherosclerosis	7.6e-06	2.2e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—TGFB1—atherosclerosis	7.49e-06	2.16e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—NOS3—atherosclerosis	7.48e-06	2.16e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—IL6—atherosclerosis	7.44e-06	2.15e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—IL6—atherosclerosis	7.18e-06	2.07e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—IL6—atherosclerosis	7.14e-06	2.06e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PIK3CG—atherosclerosis	6.95e-06	2.01e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—AKT1—atherosclerosis	6.86e-06	1.98e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PTGS2—atherosclerosis	6.84e-06	1.98e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—IL6—atherosclerosis	6.84e-06	1.98e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PPARG—atherosclerosis	6.71e-06	1.94e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—AKT1—atherosclerosis	6.62e-06	1.91e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—AKT1—atherosclerosis	6.59e-06	1.9e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—INS—atherosclerosis	6.58e-06	1.9e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—AKT1—atherosclerosis	6.31e-06	1.82e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—IL6—atherosclerosis	6.3e-06	1.82e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—AKT1—atherosclerosis	6.23e-06	1.8e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—IL6—atherosclerosis	6.2e-06	1.79e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—IL6—atherosclerosis	6.07e-06	1.75e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ALB—atherosclerosis	6.03e-06	1.74e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—AKT1—atherosclerosis	5.82e-06	1.68e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—NOS3—atherosclerosis	5.77e-06	1.67e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—AKT1—atherosclerosis	5.72e-06	1.65e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—IL6—atherosclerosis	5.64e-06	1.63e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—AKT1—atherosclerosis	5.6e-06	1.62e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PTGS2—atherosclerosis	5.28e-06	1.52e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—AKT1—atherosclerosis	5.21e-06	1.5e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—AKT1—atherosclerosis	4.3e-06	1.24e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—AKT1—atherosclerosis	3.44e-06	9.93e-06	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—AKT1—atherosclerosis	2.65e-06	7.66e-06	CbGpPWpGaD
